Nebivolol for heart failure in the elderly

References

• Mosterd A, Hoes AW, de-Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population – the Rotterdam study. Eur. Heart J.20, 447–455 (1999).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Stewart S. Heart failure. Epidemiology, etiology and prognosis of heart failure. Heart83, 596–602 (2000).
   PubMed Web of Science ®Google Scholar
• Cowie MR, Fox KF Wood DA et al. Hospitalisation of patients with heart failure. A population-based study. Eur. Heart J.23, 877–885 (2002).
   PubMed Web of Science ®Google Scholar
• Redfield MM. Heart failure an epidemic of uncertain proportion. N. Engl. J. Med.347, 1442–1444 (2002).
   PubMed Web of Science ®Google Scholar
• Stewart S, McIntyre K, Capewell S et al. Heart failure and the aging population: an increasing burden in the 21st century? Heart89, 49–53 (2003).
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Opasich C. Clinical epidemiology of heart failure. Congest. Heart Fail.5, 260–269 (1999).
   PubMedGoogle Scholar
• Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart study. Circulation106, 3068–3072 (2002).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Swedberg K, Follath F et al. The Euro Heart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Eur. Heart J.24, 442–463 (2003).
   PubMed Web of Science ®Google Scholar
• Varadarajan P, Pai RG. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2258 hospitalized patients. J. Card. Fail.9, 107–112 (2003).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Gemmell I, Khand A et al. Is the prognosis of heart failure improving? Eur. J. Heart Fail.1, 229–141 (1999).
   PubMed Web of Science ®Google Scholar
• MacIntyre K, Capewell S, Stewart S et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66547 patients hospitalized between 1986 and 1995. Circulation102, 1126–1131 (2000).
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Lichtman JH, Heidenreich PA et al. National trends in outcomes among elderly patients with heart failure. Am. J. Med.119, e1–e7 (2006).
   Google Scholar
• Owen A. Life expectancy of elderly and very elderly patients with chronic heart failure. Am. Heart J.151, e1–e4 (2006).
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med.355, 251–259 (2006).
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart J.27, 65–75 (2006).
   PubMed Web of Science ®Google Scholar
• Shibata MC, Flather MD, Wang D. Systematic review of the impact of β-blockers on mortality and hospital admission in heart failure. Eur. J. Heart Fail.3, 351–357 (2001).
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Gottlieb S, Ghali JK et al. Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur. Heart J.25, 1300–1309 (2004).
   PubMed Web of Science ®Google Scholar
• Erdmann E, Lechat P, Verkenne P et al. Results from post-hoc analysis of the CIBIS II trial: effect of bisoprolol in high risk patient groups with chronic heart failure. Eur. J. Heart Fail.3, 469–479 (2001).
   PubMed Web of Science ®Google Scholar
• Tarantini L, Faggiano P, Senni M et al. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian network on congestive heart failure. Ital. Heart J.3, 656–664 (2002).
   PubMedGoogle Scholar
• Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation98, 2282–2289 (1998).
   PubMed Web of Science ®Google Scholar
• Pernenkil R, Vinson J, Shah AS et al. Course and prognosis in patients >= 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am. J. Cardiol.79, 216–219 (1997).
   PubMed Web of Science ®Google Scholar
• Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population based study. N. Engl. J. Med.355, 260–269 (2006).
   PubMed Web of Science ®Google Scholar
• Chen HH, Lainchbury JG, Senni M et al. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J. Card. Fail.8, 279–287 (2002).
   PubMed Web of Science ®Google Scholar
• Smart N, Haluska B, Leano R et al. Determinants of functional capacity in patients with chronic heart failure: role of filling pressure and systolic and diastolic function. Am. Heart J.149, 152–158 (2005).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland JG, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J.26, 1115–1140 (2005).
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised Intervention trial in congestive heart failure (MERIT- HF). Lancet353, 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JGF et al. for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet362, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med.344, 1651–1658 (2001).
   PubMed Web of Science ®Google Scholar
• CIBIS II investigators and Committees. The Cardiac Insufficiency Bisoprolol Study-II (CIBIS II): a randomised trial. Lancet353, 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ et al. Randomzed trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J.26, 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Lechat P, Packer M, Chalon S et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation98, 1184–1191 (1998).
   PubMed Web of Science ®Google Scholar
• Komajda M, Follath F, Swedberg K et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euroheart Failure Survey programme. A survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J.24, 464–474 (2003).
   PubMed Web of Science ®Google Scholar
• Komajda M, Lapuerta P, Hermans N et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur. Heart J.26, 1653–1659 (2005).
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Sinagra G, Opasich C et al. Treatment of chronic heart failure with adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart89, 299–305 (2003).
   PubMed Web of Science ®Google Scholar
• Brixius K, Bundkirchen, Bolck B et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br. J. Pharmacol.133, 1330–1336 (2001).
   PubMed Web of Science ®Google Scholar
• Ignarro LJ, Byrns RE, Trinh K et al. Nebivolol: a selective β1-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide7, 75–82 (2002).
   PubMed Web of Science ®Google Scholar
• Altwegg LA, d’Uscio LV, Barandier C et al. Nebivolol induces NO-mediated relaxations of rat small resistance but not of large elastic arteries. J. Cardiovasc. Pharmacol.36, 316–320 (2000).
   PubMed Web of Science ®Google Scholar
• Ignarro LJ. Experimental evidence of vasodilatory activity of nebivolol, a third generation β-blocker. Blood Press.13(Suppl. 1), 2–16 (2004).
   Web of Science ®Google Scholar
• Cosentino F, Bonetti S, Rehorik R et al. Nitric oxide-mediated relaxations in salt-induced hypertension: effect of chronic β1-selective receptor blockade. J. Hypertens.20, 421–428 (2002).
   PubMed Web of Science ®Google Scholar
• Cockcroft JR, Chowienczyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO dependent mechanism. J. Pharmacol. Exp. Ther.374, 1067–1071 (1995).
   Google Scholar
• Dawes M, Brett SE, Chowienczyk PJ et al. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br. J. Clin. Pharmacol.48, 460–463 (1999).
   PubMed Web of Science ®Google Scholar
• Tzemos N, Lim OP, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A double blind and placebo controlled study. Circulation104, 511–514 (2001).
   PubMed Web of Science ®Google Scholar
• De Groot AA, Mathy MJ, van Zwieten PA et al. Involvement of the β3-adrenoceptors in nebivolol-induced vasorelaxation in the rat aorta. J. Cardiovasc. Pharmacol.42(2), 232–236 (2003).
   PubMed Web of Science ®Google Scholar
• Dessy C, Saliez J, Ghisdal P et al. Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation112, 1198–1205 (2005).
   PubMed Web of Science ®Google Scholar
• Wisenbaugh T, Katz I, Davis J et al. Long term (3 months) effect of a new β-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J. Am. Coll. Cardiol.21, 1094–1100 (1993).
   PubMed Web of Science ®Google Scholar
• Nodari S, Metra M, Dei Cas L. β blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. Eur. J. Heart Fail.5(5), 621–627 (2003).
   PubMed Web of Science ®Google Scholar
• Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am. J. Cardiol.92, 344–348 (2003).
   PubMed Web of Science ®Google Scholar
• Brett SE, Forte P, Dawes M et al. A comparison of the effects of nebivolol and bisoprolol on systemic vascular resistance in patients with essential hypertension. Clin. Drug Invest.22, 355–359 (2002).
   Web of Science ®Google Scholar
• Storelu L, Wijns W, Bouvy T et al. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic functions: comparison with D-L-nebivolol and atenolol. J. Card. Pharmacol.22, 183–190 (1993).
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Chapelle F, Van Eyll C et al. Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J. Card. Fail.2, 15–23 (1996).
   PubMedGoogle Scholar
• Brune S, Tebbe U, Schmidt T et al. Haemodynamic effects of nebivolol, at rest and exertion in patients with heart failure. Angiology41, 696–701 (1990).
   PubMed Web of Science ®Google Scholar
• Boutelant S, Lechat P, Komajda M et al. Non invasive evaluation of cardiovascular effects of nebivolol in patients with cardiac insufficiency. Arch. Mal. Coeur Vaiss.85, 863–870 (1992).
   PubMedGoogle Scholar
• Ghio S, Magrini G, Serio A et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur. Heart J.27, 562–568 (2006).
   PubMed Web of Science ®Google Scholar
• Edes I, Gasior Z,Wita K et al. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur. J. Heart Fail.7, 631–639 (2005).
   PubMed Web of Science ®Google Scholar
• Di Lenarda A, Scherillo M, Maggioni AP et al. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds – The TEMISTOCLE study. Am. Heart J.146, e12 (2003).
   PubMedGoogle Scholar
• Opasich C, Boccanelli A, Cafiero M et al. Programme to improve the use of b-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 study. Eur. J. Heart Fail.8, 649–657 (2006).
   PubMed Web of Science ®Google Scholar
• MacDonald PS, Hill J, Krum H, for the COLA II Investigators. The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA II Study. Am. J. Cardiovasc. Drugs6, 401–405 (2006).
   PubMedGoogle Scholar
• Moen MD, Wagstaff AJ. Nebivolol – a rewiew of its use in the management of hypertension and chronic heart failure. Drugs66, 1389–1409 (2006).
   PubMed Web of Science ®Google Scholar
• Patrianakos AP, Parthenakis FI, Mavrakis HE et al. Effects of nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study. Hellenic J. Cardiol.46, 199–207 (2005).
   PubMedGoogle Scholar
• Lombardo RM, Reina C, Abrignoni MG et al. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am. J. Cardiovasc. Drugs6, 259–263 (2006).
   PubMedGoogle Scholar
• Morgan DR, Dixon LJ, Hanratty CJ et al. Impaired endothelium-dependent and -independent vasodilation in elderly patients with chronic heart failure. Eur. J. Heart Fail.6, 901–908 (2004).
   PubMed Web of Science ®Google Scholar
• McMurray J. Making sense of SENIORS. Eur. Heart J.26(3), 203–206 (2005).
   PubMedGoogle Scholar
• Coats AJ. β-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents. Drugs Aging23, 93–99 (2006).
   PubMed Web of Science ®Google Scholar